Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous SCC for Immunocompromised Patients

Study Summary

This is a multi-center clinical study enrolling up to 28 participants. The primary objectives are to determine the objective response rate (ORR) established by the confirmed best overall response (BOR) following intratumoral administration of DaRT - Diffusing Alpha-Emitters Radiation Therapy. Secondary objectives are to: 1. Determine Progression Free Survival (PFS) up to 12 months after Alpha DaRT sources insertion. 2. Assess Overall Survival (OS) of patients treated with DaRT up to 12 months. 3. Assess Local control up to 12 months after DaRT insertion.

Conditions

Squamous Cell Carcinoma Alpha Radiation Immunocompromised Carcinoma, Squamous Skin Cancer Brachytherapy

Interventions / Drugs

DaRT seeds

View on ClinicalTrials.gov ↗

Sponsor

DRTS

Alpha Tau Medical Ltd.

Biotech / Pharma

F17/100

Study Details

Enrollment28 participants

Primary Completion—

Lead SponsorAlpha Tau Medical LTD.

Data Retrieved2026-06-17 02:56:49.846114+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.